



August 1, 2007 04:13 PM US Eastern Standard Time

Capricor Announces Relocation to Los Angeles, California

Baltimore, Maryland. – August 1, 2007. Capricor Inc. (www.capricor.com) today announced that it is relocating operation to Los Angeles California. The move parallels the move of scientific founder, Eduardo Marbán M.D., from Johns Hopkins University School of Medicine to Cedars-Sinai Medical Center.

Dr. Marbán is to become Director of the Cedars-Sinai Heart Institute in the fall. In addition to overseeing cardiac surgery, cardiology, and cardiac imaging at Cedars, Dr. Marbán will expand the Los Angeles based center's cardiology research. Dr. Marbán's research focuses on the molecular and cellular mechanisms involved in arrhythmias, heart failure, and MI, with a publication record of more than 300 peer-reviewed papers.

Capricor will move all operations to Los Angeles by the end of September. Capricor plans to locate in Beverly Hills near Cedars and Dr. Marbán's laboratories. "Proximity is a crucial part of continuing the excellent collaboration that Capricor has enjoyed with its academic partners," said Oliver Foellmer, President and CEO of Capricor. "Los Angeles is a dynamic environment for stem cell science with new centers being established not only at Cedars, but also at UCLA and USC. With the Proposition 71 stem cell initiative coming into its own, California provides and excellent business environment for any regenerative medicine company."

Capricor Inc., located in Los Angeles, California, is a leading biotechnology company that specializes in discovering, developing, and commercializing biotherapeutics for the treatment of heart diseases. Capricor's mission is to revolutionize the treatment of cardiac disease by translating novel stem cell science into therapeutics that halt and reverse the disease process for patient's, their families, and society in general.

***Translating today's cardiac research innovations
into tomorrow's heart therapies***